 |
Journal articles
ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
Abstract : The identification of unique cell-surface proteins expressed on tumor cells, yet not expressed on normal tissues, has been challenging for pediatric malignancies. The cell sur-face tyrosine kinase ALK (CD246, anaplastic lymphoma kinase) is a promising target for neuroblastoma in that it is expressed in either native, mutated, or over-expressed forms on the plasma membrane surface
https://www.hal.inserm.fr/inserm-00881036
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Thursday, November 7, 2013 - 1:14:47 PM
Last modification on : Sunday, June 26, 2022 - 9:48:41 AM
Long-term archiving on: : Saturday, February 8, 2014 - 7:15:08 AM
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Thursday, November 7, 2013 - 1:14:47 PM
Last modification on : Sunday, June 26, 2022 - 9:48:41 AM
Long-term archiving on: : Saturday, February 8, 2014 - 7:15:08 AM